LEADERSHIP

As President and CEO of Organogenesis Inc., Gary S. Gillheeney, Sr. has led the company's growth and development for more than 15 years. When Mr. Gillheeney joined the company as CFO/COO, Organogenesis had just launched its first product, Apligraf^® in wound care. Under his guidance, the company has grown, both through organic development as well as acquisitions, into its current position as a leading regenerative medicine company offering a portfolio of products for the advanced wound care and surgical biologics markets. For his work at Organogenesis, Mr. Gillheeney was recognized in 2009 as an Ernst & Young's "Entrepreneur of the Year." He has also served in leadership positions in the biotech and regenerative medicine fields, including his current role on the Massachusetts Biotechnology Council (MassBio) Board of Directors. Also, Mr. Gillheeney is on the Board of Trustees at American International College.

Mr. Gillheeney's career in Executive Management, Operations and Finance spans more than 25 years. Prior to joining Organogenesis, he held executive positions at Innovative Clinical Solutions, Ltd. as Chief Operating Officer, Chief Financial Officer, as well as Treasurer and Secretary. Prior to that he held positions as Senior Vice President, Chief Financial Officer, Treasurer, and Assistant Secretary at Providence Energy Corporation. Mr. Gillheeney has a B.S. in Accounting from American International College and an MBA from Bryant College.

David C. Francisco has served as our Chief Financial Officer since 2021. Prior to joining Organogenesis, Mr. Francisco spent 20 years at PerkinElmer, Inc. (NYSE: PKI), a leading provider of products, services and solutions for the diagnostics, life sciences and applied markets, where he most recently served as Vice President and Treasurer. During his tenure at PKI, he held a series of leadership roles of increasing responsibility across multiple business areas, including as Vice President, Investor Relations and Vice President of Financial Operations as well as Chief Financial Officer of its Human Health segment. Mr. Francisco holds a Bachelor of Science degree in Industrial Engineering & Operations Research from the University of Massachusetts, Amherst, as well as an M.B.A. from the McCallum Graduate School of Business at Bentley University.

Patrick Bilbo has served as our Chief Operating Officer since 2017. Previously, he served as our Senior Vice President, Regulatory, Government Affairs and Administration and other executive positions from 1999 to 2017. His career in regenerative medicine, biotechnology and medical devices spans more than 30 years, and he has had a technical and leadership role in the successful development and commercialization of numerous products. Prior to joining Organogenesis, he held management and research positions at Hologic Corporation (Cytyc), Stryker Corporation and Harvard Medical School. Mr. Bilbo earned an M.B.A. from the Boston University Questrom School of Business, and Masters Degrees in Biology and Technology Strategy & Policy from the Boston University Graduate School of Arts & Sciences, and a B.S. degree in Biology from Syracuse University.

Brian Grow has served as our Chief Commercial Officer since 2017. Since 2004, he has served in a number of roles at Organogenesis with increasing responsibility, including as our Director of Sales, Commercial Operations, from 2013 to 2016, Associate Director, Marketing, from 2012 to 2013, Project Manager—Apligraf from 2011 to 2013, Regional Sales Manager from 2006 to 2011 and Tissue Regeneration Specialist from 2004 to 2006. Prior to joining Organogenesis, he was a pharmaceutical sales representative for Bristol-Myers Squibb from 2003 to 2004 and a tissue engineering specialist for Innovex/Novartis from 2000 to 2003. Mr. Grow earned a B.A. in Psychology from William Jewell College.

Lori Freedman has served as our Chief Administrative and Legal Officer since 2023. She joined Organogenesis in 2017 and had served as Vice President and General Counsel since 2018. Previously, she served as Vice President, Corporate Affairs & General Counsel of pSivida Corp., a specialty biopharmaceutical company, from 2001 to 2016 and as Vice President, General Counsel for Allaire Corporation, a computer software company, from 1998 to 2001. Mrs. Freedman holds a J.D. from the Boston University School of Law and a B.A. in economics and psychology from Brandeis University.

Antonio S. Montecalvo has served as our Vice President, Health Policy since 2017. Since 2003, he has served in various roles at Organogenesis, including as Director of Customer Support Services from 2003 to 2006. Prior to joining Organogenesis, Mr. Montecalvo served as Director of Accounting for Innovative Clinical Solutions, LTD from 2000 to 2003, as Senior Contracts Specialist for UnitedHealth Group from 1996 to 2000 and as a Senior Accountant for Piccerelli, Gilstein & Company, LLP from 1994 to 1996. Mr. Montecalvo holds a B.S. in Accounting from the University of Rhode Island.

Robert Cavorsi has served as our Vice President, Strategy since 2021. With over 16 years of experience at Organogenesis, he has served as Executive Director, Commercial Development and Strategy in 2020, Senior Director, Sales in 2018 to 2020, Director, Sales Performance and Operations from 2016 to 2017. He served as Director, Sales Operations - Neurology at Sunovion Pharmaceuticals from 2015 to 2016. Before this, Mr. Cavorsi held various roles of increasing responsibility at Organogenesis in Sales, Marketing, National Accounts, and Business Relations from 2004 to 2015. Prior to joining Organogenesis, Mr. Cavorsi served as Product Specialist and Wound Care Sales Specialist at PDI, Inc. in 2003 and as a Tissue Engineering Specialist for Novartis in 2002 to 2003. Mr. Cavorsi holds a B.S. in Health Policy and Administration from The Pennsylvania State University.

Zorina Pitkin has served as our Senior Vice President, Quality Systems since 2008. Prior to joining the company, Dr. Pitkin served as Acting Head, Regulatory Affairs at Tolerx, Inc. From 2002 to 2007, she was Senior Vice President, Regulatory and Quality for RenaMed Biologics, Inc., and she also served as Vice President, Regulatory and Quality at Circe Biomedical from 1996 to 2002. Dr. Pitkin's range of expertise includes the development of Quality System programs and regulatory strategies for cellular therapies, biologic/device combination products, biologics and xenotransplantation. She holds a Ph.D. in Biological Sciences from the Research Institute of Influenza, Russian Academy of Medical Sciences, and is Regulatory Affairs certified. She has served as a member of the USP Tissue and Tissue-based Products Advisory Panel and as a member of the Regulatory Affairs Professional Society Board of Directors.

Kurt Matheson has served as our Vice President, Marketing since 2021. Prior to joining Organogenesis, Mr. Matheson gained over 20 years of experience in healthcare at industry-leading organizations. From 2018 to 2021, he held the Vice President of Marketing and Vice President of Sales & Marketing roles at Novanta Inc. From 2016 to 2018, he served as Senior Director of Marketing at Stryker. From 2000 to 2016, he held various Sales and Marketing roles of increasing responsibility in both the Advanced Wound Care and Surgical Divisions of Ethicon at Johnson & Johnson culminating in his final role as Director, Global Strategic Marketing. Mr. Matheson graduated from The United States Military Academy at West Point and served his country for 5 years as an officer in the Army (Captain) where he developed his leadership skills early on in his professional career.

Mark Collins has served as our Vice President, Business Relations & Corporate Accounts since 2021. Prior to joining Organogenesis, Mr. Collins served as Director, Strategic Sourcing at HealthTrust Performance Group from 2012 to 2021. From 2009 to 2012, he served as Contracting Officer at United States Army Security Assistance Command. He began his career in the United States Army from 1989 to 2009. Mr. Collins holds an Masters in Government Procurement and Contracting from Florida Institute of Technology.